Skip to content
NJ News HubNewsHub

Business

Johnson & Johnson names new Innovative Medicine leader

Source: NJBiz · Aug 5, 2026, 7:10 AM

AI-assisted briefing from the publisher’s public headline and excerpt — not original reporting. How we write briefings

Johnson & Johnson names new Innovative Medicine leader news image

Johnson & Johnson announced Tom Cavanaugh as the new leader of its Innovative Medicine division, following the retirement of Jennifer Taubert after more than two decades with the company.

Taubert's departure marks a significant leadership transition at the pharmaceutical giant's New Jersey headquarters. Cavanaugh's appointment reflects J&J's continued strategic focus on its innovative medicine business unit, a core component of the company's portfolio.

Key points

  • Tom Cavanaugh named new head of J&J's Innovative Medicine division
  • Jennifer Taubert retiring after 21+ years with Johnson & Johnson
  • Leadership change reflects J&J's strategic priorities in innovative pharmaceutical development
  • J&J based in New Brunswick, New Jersey

FAQ

Who is replacing Jennifer Taubert at Johnson & Johnson?
Tom Cavanaugh has been named to lead the Innovative Medicine division, replacing Jennifer Taubert who is retiring after more than 21 years with the company.
Why is Jennifer Taubert leaving Johnson & Johnson?
Jennifer Taubert is retiring after serving the company for over 21 years. The announcement did not specify additional retirement reasons beyond her tenure with the organization.
What is the Innovative Medicine division at J&J?
Innovative Medicine is a key business unit at Johnson & Johnson focused on developing and delivering cutting-edge pharmaceutical solutions. It represents a significant part of the company's overall business strategy.

Briefing prepared for NJ News Hub. Verify details on the original story. See our editorial policy.

Related